Acute myeloid leukemia

Childhood Leukemias, Second Edition

Volumn , Issue , 2006, Pages 499-539

  Rubnitz, Jeffrey E ^a   Razzouk, Bassem I ^a   Ribeiro, Raul C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74949086411     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511471001.020     Document Type: Chapter

References (390)

1. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 1997; 3: 730-7.
2. Stevens, R. F., Hann, I. M., Wheatley, K., et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol, 1998; 101: 130-40.
3. Woods, W. G., Neudorf, S., Gold, S., et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrowtransplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood, 2001; 97: 56-62.
4. Creutzig, U., Ritter, J., Zimmermann, M., et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol, 2001; 19: 2705-13.
5. O'Brien, T. A., Russell, S. J., Vowels, M. R., et al. Results of consecutivetrials for childrennewlydiagnosedwithacutemyeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood, 2002; 100: 2708-16.
6. Smith, M. A., Ries, L. A. G., Gurney, J. G., &Ross, J. A. Leukemia. In:L.A.G. Ries, M.A. Smith, J.G. Gurney, et al., eds., Cancer Incidence and Survival among Children and Adolescents: United States SEERProgram1975-1995. (Bethesda, MD:National Cancer Institute, SEER Program, 1999), pp. 17-31.
7. Parkin, D. M., Stiller, C. A., Draper, G. J., et al. International Incidence of Childhood Cancer, IARC Scientific Publications 87 (Lyon, France: IARC, 1988).
8. Bhatia, S. & Neglia, J. P. Epidemiology of childhood acute myelogenous leukemia. J Pediatr Hematol Oncol, 1995; 17: 94-100.
9. Douer, D., Preston-Martin, S., Chang, E., et al. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood, 1996; 87: 308-13.
10. Zimmerman, L. E. & Font, R. L. Ophthalmologic manifestations of granulocytic sarcoma(myeloid sarcomaor chloroma). The third Pan American Association of Ophthalmology and American Journal of Ophthalmology Lecture. Am J Ophthalmol, 1975; 80: 975-90.
11. Cavdar, A. O., Babacan, E., Gozdasoglu, S., et al. High risk subgroup of acute myelomonocytic leukemia (AMML) with orbito-ocular granulocytic sarcoma (OOGS) in Turkish children. Retrospective analysis of clinical, hematological, ultrastructural and therapeutical findings of thirty-three OOGS. Acta Haematol, 1989; 81: 80-5.
12. Gamis, A. S. Acute myeloid leukemia and Down syndrome: evolution of modern therapy-state of the art review. Pediatr Blood Cancer, 2005; 44: 13-20.
13. Ross, J. A., Spector, L. G., Robison, L. L., et al. Epidemiology of leukemia in children with Down syndrome. Pediatr Blood Cancer, 2005; 44: 8-12.
14. Rosenberg, P. S., Greene, M. H., & Alter, B. P. Cancer incidence in persons with Fanconi anemia. Blood, 2003; 101: 822-6.
15. German, J. Bloom's syndrome. The first 100 cancers. Cancer Genet Cytogenet, 1997; 93: 100-6.
16. Bader, J. L. & Miller, R. W. Neurofibromatosis and childhood leukemia. J Pediatr, 1978; 92: 925-9.
17. Bader-Meunier, B., Tchernia, G., Mielot, F., et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr, 1997; 130: 885-9.
18. Freedman, M. H. & Alter, B. P. Malignant myeloid transformation in congenital forms of neutropenia. Isr Med Assoc J, 2002; 4: 1011-14.
19. Song, W. J., Sullivan, M. G., Legare, R. D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet, 1999; 23: 166-75.
20. Baranger, L., Baruchel, A., Leverger, G., et al. Monosomy-7 in childhood hemopoietic disorders. Leukemia, 1990; 4: 345-9.
21. Luna-Fineman, S., Shannon, K. M., & Lange, B. J. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood, 1995; 85: 1985-99.
22. Brill, A., Tomonaga, M., & Heyssel, R. M. Leukemia in man followingexposureto ionizing radiation. Ann Intern Med, 1962; 56: 590-609.
23. Noshchenko, A. G., Zamostyan, P. V., Bondar, O. Y., et al. Radiation-induced leukemia risk among those aged 0-20 at the time of the Chernobyl accident: a case-control study in the Ukraine. Int J Cancer, 2002; 99: 609-18.
24. Smith, M. A., McCaffrey, R. P., & Karp, J. E. The secondary leukemias: challenges and research directions. J Natl Cancer Inst, 1996; 88: 407-18.
25. Pui, C. H., Ribeiro, R. C., Hancock, M. L., et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. NEngl J Med, 1991; 325: 1682-7.
26. Sandler, D. P. Epidemiology and etiology of acute leukemia: an update. Leukemia, 1992; 6 (Suppl. 4): 3-5.
27. Sandler, D. P. & Ross, J. A. Epidemiology of acute leukemia in children and adults. Semin Oncol, 1997; 24: 3-16.
28. Ma, X., Buffler, P. A., Gunier, R. B., et al. Critical windows of exposure to household pesticides and risk of childhood leukemia. Environ Health Perspect, 2002; 110: 955-60.
29. Rinsky, R. A., Hornung, R.W., Silver, S. R., et al. Benzene exposure and hematopoietic mortality: a long-termepidemiologic risk assessment. Am J Ind Med, 2002; 42: 474-80.
30. Steinbuch, M., Weinberg, C. R., Buckley, J.D., et al. Indoor residential radon exposure and risk of childhood acute myeloid leukaemia. Br J Cancer, 1999; 81: 900-6.
31. Ahlbom, I. C., Cardis, E., Green, A., et al. Review of the epidemiologic literature on EMF and Health. Environ Health Perspect, 2001; 109 (Suppl. 6): 911-33.
32. Relling, M. V. & Dervieux, T. Pharmacogenetics and cancer therapy. Nat Rev Cancer, 2001; 1: 99-108.
33. Krajinovic, M., Richer, C., Sinnett, H., et al. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev, 2000; 9: 557-62.
34. Woo, M. H., Shuster, J. J., Chen, C., et al. Glutathione Stransferase genotypes in children who develop treatmentrelated acute myeloid malignancies. Leukemia, 2000; 14: 232-7.
35. Schwahn, B. & Rozen, R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics, 2001; 1: 189-201.
36. Smith, M. A., Chen, T., & Simon, R. Age-specific incidence of acute lymphoblastic leukemia in U.S. children: in utero initiation model. J Natl Cancer Inst, 1997; 89: 1542-4.
37. Rowley, J.D. Backtracking leukemia to birth. Nat Med, 1998; 4: 150-1.
38. Ross, J. A., Potter, J.D., & Robison, L. L. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst, 1994; 86: 1678-80.
39. Ross, J. A. Dietary flavonoids and the MLL gene: a pathway to infant leukemia? Proc Natl Acad Sci U S A, 2000; 97: 4411-13.
40. Speck, N. A. & Gilliland, D. G. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer, 2002; 2: 502-13.
41. Tenen, D. G. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer, 2003; 3: 89-101.
42. Stirewalt, D. L.&Radich, J.P. Therole of FLT3inhaematopoietic malignancies. Nat Rev Cancer, 2003; 3: 650-65.
43. Gilliland, D. G. & Griffin, J. D. The roles of FLT3 in hematopoiesis and leukemia. Blood, 2002; 100: 1532-42.
44. Pabst, T., Mueller, B. U., Zhang, P., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet, 2001; 27: 263-70.
45. Downing, J. R. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol, 1999; 106: 296-308.
46. Higuchi, M., O'Brien, D., Kumaravelu, P., et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell, 2002; 1: 63-74.
47. Meshinchi, S., Stirewalt, D. L., Alonzo, T. A., et al. Activating mutations of RTK/ras signal transductionpathwayin pediatric acute myeloid leukemia. Blood, 2003; 102: 1474-9.
48. Head, D. R. Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful? Curr Opin Oncol, 2002; 14: 19-23.
49. Bennett, J. M., Catovsky, D., Daniel, M. T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol, 1976; 33: 451-8.
50. Bennett, J. M., Catovsky, D., Daniel, M. T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med, 1985; 103: 620-5.
51. Bennett, J. M., Catovsky, D., Daniel, M. T., et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med, 1985; 103: 460-2.
52. Bennett, J. M., Cassileth, P. A., Paietta, E., et al. Morphologic classification of acute myeloid leukemia: concordance among Eastern Cooperative Oncology Group investigators: a comment. Leukemia, 1996; 10: 1365.
53. Head, D. R. Revised classification of acute myeloid leukemia. Leukemia, 1996; 10: 1826-31.
54. Chan, G. C., Wang, W. C., Raimondi, S. C., et al. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Leukemia, 1997; 11: 206-11.
55. Jaffe, E. S., Harris, N. L., Stein, H., &Vardiman, J.W., eds., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues 3rd edn. (Lyon, France: IARC, 2001).
56. Vardiman, J. W., Harris, N. L., & Brunning, R. D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002; 100: 2292-302.
57. Chan, J. K. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol, 2001; 19: 129-50.
58. Hasle, H., Niemeyer, C. M., Chessells, J. M., et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 2003; 17: 277-82.
59. Resnik, K. S. & Brod, B. B. Leukemia cutis in congenital leukemia. Analysis and review of the world literature with report of an additional case. Arch Dermatol, 1993; 129: 1301-6.
60. Kaddu, S., Zenahlik, P., Beham-Schmid, C., et al. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria. J Am Acad Dermatol, 1999; 40: 966-78.
61. Sansone, R., Haupt, R., Strigini, P., et al. Congenital leukemia: persistent spontaneous regression in a patient with an acquired abnormal karyotype. Acta Haematol, 1989; 81: 48-50.
62. Bresters, D., Reus, A. C., Veerman, A. J., et al. Congenital leukaemia: the Dutch experience and review of the literature. Br J Haematol, 2002; 117: 513-24.
63. Grundy, R. G., Martinez, A., Kempski, H., et al. Spontaneous remissionof congenital leukemia:acase forconservativetreatment. J Pediatr Hematol Oncol, 2000; 22: 252-5.
64. Ribeiro, R. C. & Pui, C. H. The clinical and biological correlates of coagulopathy in children with acute leukemia. J Clin Oncol, 1986; 4: 1212-18.
65. Ravandi-Kashani, F., Cortes, J., & Giles, F. J. Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome. Leuk Lymphoma, 2000; 36: 631-7.
66. Nounou, R., Al Zahrani, H. H., Ajarim, D. S., et al. Extramedullary myeloid cell tumours localised to the mediastinum: a rare clinicopathological entity with unique karyotypic features. J Clin Pathol, 2002; 55: 221-5.
67. Nichols, C. R., Roth, B. J., Heerema, N., et al. Hematologic neoplasia associated with primary mediastinal germ-cell tumors. NEngl J Med, 1990; 322: 1425-9.
68. Ross, M. E., Mahfouz, R., Onciu, M., et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood, 2004; 104: 3679-87.
69. Pinkel, D. & Woo, S. Prevention and treatment of meningeal leukemia in children. Blood, 1994; 84: 355-66.
70. Dahl, G. V., Simone, J. V., Hustu, H. O., et al. Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer, 1978; 42: 2187-92.
71. Stavem, P. & Evensen, S. A. CNS involvement in acute myelomonoblastic leukemia. Br J Haematol, 1984; 58: 383-4.
72. Pui, C. H., Dahl, G. V., Kalwinsky, D. K., et al. Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood, 1985; 66: 1062-7.
73. Amadori, S., Ceci, A., Comelli, A., et al. Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM8204. J Clin Oncol, 1987; 5: 1356-63.
74. Ravindranath, Y., Steuber, C. P., Krischer, J., et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J Clin Oncol, 1991; 9: 572-80.
75. Woods, W. G., Kobrinsky, N., Buckley, J. D., et al. Timedsequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood, 1996; 87: 4979-89.
76. Webb, D. K., Harrison, G., Stevens, R. F., et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood, 2001; 98: 1714-20.
77. Creutzig, U., Ritter, J., Zimmermann, M., et al. Doescranial irradiation reducetherisk forbonemarrowrelapseinacutemyelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol, 1993; 11: 279-86.
78. Weinstein, H. J., Mayer, R. J., Rosenthal, D. S., et al. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood, 1983; 62: 315-19.
79. Pui, C. H., Rivera, G., Mirro, J., et al. Acute megakaryoblastic leukemia. Blast cell aggregates simulating metastatic tumor. Arch Pathol Lab Med, 1985; 109: 1033-5.
80. Daliphard, S., Behar, C., Cornillet-Lefebvre, P., et al. Acute megakaryoblastic leukemia in an infant mimicking polycystic kidney disease. Med Pediatr Oncol, 2002; 38: 53-4.
81. Wiemels, J. L., Xiao, Z., Buffler, P. A., et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood, 2002; 99: 3801-5.
82. Mori, H., Colman, S. M., Xiao, Z., et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A, 2002; 99: 8242-7.
83. Perel, Y., Auvrignon, A., Leblanc, T., et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. J Clin Oncol, 2002; 20: 2774-82.
84. Lie, S. O., Jonmundsson, G., Mellander, L., et al. A populationbased study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's Cambridge Books Online (c) Cambridge University Press, 2009 Acute myeloid leukemia 529 syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol, 1996; 94: 82-8.
85. Krance, R. A., Hurwitz, C. A., Head, D. R., et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol, 2001; 19: 2804-11.
86. Creutzig, U., Ritter, J., Zimmermann, M., et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol, 2001; 19: 2705-13.
87. Ravindranath, Y., Yeager, A. M., Chang, M. N., et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acutemyeloid leukemia in childhood. Pediatric Oncology Group. NEngl J Med, 1996; 334: 1428-34.
88. Raimondi, S. C., Chang, M. N., Ravindranath, Y., et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Groupstudy-POG8821. Blood, 1999; 94: 3707-16.
89. Forestier, E., Heim, S., Blennow, E., et al. Cytogenetic abnormalities in childhood acutemyeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haematol, 2003; 121: 566-77.
90. Grimwade, D., Walker, H., Oliver, F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998; 92: 2322-33.
91. Byrd, J. C., Mrozek, K., Dodge, R. K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancerand Leukemia Group B(CALGB8461). Blood, 2002;100: 4325-36.
92. Wolman, S. R., Gundacker, H., Appelbaum, F. R., et al. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acutemyeloid leukemia: a Southwest Oncology Group study. Blood, 2002; 100: 29-35.
93. Thiede, C., Steudel, C., Mohr, B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 2002; 99: 4326-35.
94. Preudhomme, C., Sagot, C., Boissel, N., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 2002; 100: 2717-23.
95. Dohner, K., Tobis, K., Ulrich, R., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol, 2002; 20: 3254-61.
96. Sansone, R. & Negri, D. Cytogenetic features of neonatal leukemias. Cancer Genet Cytogenet, 1992; 63: 56-61.
97. Sorensen, P. H., Chen, C. S., Smith, F. O., et al. Molecular rearrangements of the MLL gene are present in most cases of infant acutemyeloid leukemiaandare strongly correlated with monocytic ormyelomonocytic phenotypes. J Clin Invest, 1994; 93: 429-37.
98. Dastugue, N., Lafage-Pochitaloff, M., Pages, M. P., et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood, 2002; 100: 618-26.
99. Pui, C. H., Ribeiro, R. C., Campana, D., et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia, 1996; 10: 952-6.
100. Chessells, J. M. Leukaemia in the young child. Br J Cancer Suppl, 1992; 18: S54-7.
101. Vormoor, J., Ritter, J., Creutzig, U., et al. Acute myelogenous leukaemia in children under 2 years-experiences of the West German AML studies BFM-78, -83 and-87. AML-BFM Study Group. Br J Cancer Suppl, 1992; 18: S63-7.
102. Chessells, J. M., Harrison, C. J., Kempski, H., et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRCChildhood Leukaemia working party. Leukemia, 2002; 16: 776-84.
103. Kawasaki, H., Isoyama, K., Eguchi, M., et al. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Blood, 2001; 98: 3589-94.
104. Rubnitz, J. E., Raimondi, S. C., Tong, X., et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol, 2002; 20: 2302-9.
105. Athale, U. H., Razzouk, B. I., Raimondi, S. C., et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood, 2001; 97: 3727-32.
106. Bloomfield, C.D. & Brunning, R.D. FAB M7: acute megakaryoblastic leukemia-beyond morphology. Ann Intern Med, 1985; 103: 450-2.
107. Tallman, M. S., Neuberg, D., Bennett, J. M., et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood, 2000; 96: 2405-11.
108. Athale, U. H., Kaste, S. C., Razzouk, B. I., et al. Skeletal manifestations of pediatric acutemegakaryoblastic leukemia. J Pediatr Hematol Oncol, 2002; 24: 561-5.
109. Hitzler, J. K. & Zipursky, A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer, 2005; 5: 11-20.
110. Crispino, J. D. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer, 2005; 44: 40-4.
111. Lightfoot, J., Hitzler, J. K., Zipursky, A., et al. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia, 2004; 18: 1617-23.
112. Ruchelli, E. D., Uri, A., Dimmick, J. E., et al. Severe perinatal liver disease and Down syndrome: an apparent relationship. Hum Pathol, 1991; 22: 1274-80.
113. Miyauchi, J., Ito, Y., Kawano, T., et al. Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down's syndrome: a report of four autopsy cases and proposal of a hypothesis. Blood, 1992; 80: 1521-7.
114. Lange, B. J., Kobrinsky, N., Barnard, D. R., et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood, 1998; 91: 608-15.
115. Zubizarreta, P., Felice, M. S., Alfaro, E., et al. Acute myelogenousleukemiain Down's syndrome:report ofasingle pediatric institution using a BFM treatment strategy. Leuk Res, 1998; 22: 465-72.
116. Wechsler, J., Greene, M., McDevitt, M. A., et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Downsyndrome. Nat Genet, 2002; 32: 148-52.
117. Mundschau, G., Gurbuxani, S., Gamis, A. S., et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood, 2003; 101: 4298-300.
118. Hitzler, J. K., Cheung, J., Li, Y., et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 2003; 101: 4301-4.
119. Xu, G., Nagano, M., Kanezaki, R., et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood, 2003; 102: 2960-8.
120. Schoch, C., Schnittger, S., Klaus, M., et al. AMLwith11q23/MLL abnormalities asdefinedby the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood, 2003; 102: 2395-402.
121. Zwaan, C. M., Kaspers, G. J., Pieters, R., et al. Different drugsensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood, 2002; 99: 245-51.
122. Kardos, G., Baumann, I., Passmore, S. J., et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood, 2003; 102: 1997-2003.
123. Carroll, W. L., Morgan, R., & Glader, B. E. Childhood bone marrow monosomy 7 syndrome: a familial disorder? J Pediatr, 1985; 107: 578-80.
124. Gilchrist, D. M., Friedman, J. M., Rogers, P. C., et al. Myelodysplasia and leukemia syndrome with monosomy 7: a genetic perspective. Am J Med Genet, 1990; 35: 437-41.
125. Gyger, M., Bonny, Y., & Forest, L. Childhood monosomy 7 syndrome. Am J Hematol, 1982; 13: 329-34.
126. Johnson, E.&Cotter, F. E. Monosomy 7 and 7q-associated with myeloid malignancy. Blood Rev, 1997; 11: 46-55.
127. Shannon, K. M., Turhan, A. G., Chang, S. S., et al. Familial bone marrow monosomy 7. Evidence that the predisposing locus is not on the long arm of chromosome 7. J Clin Invest, 1989; 84: 984-9.
128. Hasle, H., Arico, M., Basso, G., et al. Myelodysplastic syndrome, juvenilemyelomonocyticleukemia, andacutemyeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOGMDS). Leukemia, 1999; 13: 376-85.
129. Ruutu, P., Ruutu, T., Vuopie, P., et al. Defective chemotaxis in monosomy-7. Nature, 1977; 265: 146-7.
130. Ruutu, P., Ruutu, T., Repo, H., et al. Defective neutrophil migration in monosomy-7. Blood, 1981; 58: 739-45.
131. Savage, P., Frenck, R., Paderanga, D., et al. Parental origins of chromosome 7 loss in childhood monosomy 7 syndrome. Leukemia, 1994; 8: 485-9.
132. Haas, O. A. & Gadner, H. Pathogenesis, biology, and management ofmyelodysplastic syndromes in children. Semin Hematol, 1996; 33: 225-35.
133. Kalwinsky, D. K., Raimondi, S. C., Schell, M. J., et al. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol, 1990; 8: 75-83.
134. Reinhardt, D.&Creutzig, U. Isolatedmyelosarcomain children-update and review. Leuk Lymphoma, 2002; 43: 565-74.
135. Schwyzer, R., Sherman, G. G., Cohn, R. J., et al. Granulocytic sarcoma in children with acute myeloblastic leukemia and t(8;21). Med Pediatr Oncol, 1998; 31: 144-9.
136. Byrd, J. C., Edenfield, W. J., Shields, D. J., et al. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol, 1995; 13: 1800-16.
137. Ooi, G. C., Chim, C. S., Khong, P. L., et al. Radiologic manifestations of granulocytic sarcoma in adult leukemia. AJR Am J Roentgenol, 2001; 176: 1427-31.
138. Pui, M. H., Fletcher, B. D., & Langston, J. W. Granulocytic sarcoma in childhood leukemia: imaging features. Radiology, 1994; 190: 698-702.
139. Stein-Wexler, R., Wootton-Gorges, S. L., & West, D. C. Orbital granulocytic sarcoma: an unusual presentation of acute myelocytic leukemia. Pediatr Radiol, 2003; 33: 136-9.
140. Binder, C., Tiemann, M., Haase, D., et al. Isolated meningeal chloroma (granulocytic sarcoma)-a case report and review of the literature. Ann Hematol, 2000; 79: 459-62.
141. Grignani, F., Fagioli, M., Alcalay, M., et al. Acute promyelocytic leukemia: from genetics to treatment. Blood, 1994; 83: 10-25.
142. Castaigne, S., Chomienne, C., Daniel, M. T., et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia I. Clinical results. Blood, 1990; 76: 1704-9.
143. Carter, M., Kalwinsky, D. K., Dahl, G. V., et al. Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biologic features. Leukemia, 1989; 3: 298-302.
144. Biondi, A., Rovelli, A., Cantu-Rajnoldi, A., et al. Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP). Leukemia, 1994; 8(Suppl. 2): S66-70.
145. Douer, D., Preston-Martin, S., Chang, E., et al. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood, 1996; 87: 308-13.
146. Estey, E., Thall, P., Kantarjian, H., et al. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia, 1997; 11: 1661-4.
147. Thomas, X., Fiere, D., & Archimbaud, E. Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia. Leukemia, 1998; 12: 1503-6.
148. Konopleva, M., Mikhail, A., Estrov, Z., et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood, 1999; 93: 1668-76.
149. Redner, R. L., Rush, E. A., Faas, S., et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood, 1996; 87: 882-6.
150. Wells, R. A., Catzavelos, C., & Kamel-Reid, S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet, 1997; 17: 109-13.
151. Arnould, C., Philippe, C., Bourdon, V., et al. The signal transducerandactivator of transcription STAT5bgene is anewpartner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet, 1999; 8: 1741-9.
152. Chojnowski, K., Wawrzyniak, E., Trelinski, J., et al. Assessment ofcoagulationdisordersin patientswithacuteleukemiabefore and after cytostatic treatment. Leuk Lymphoma, 1999; 36: 77-84.
153. Menell, J. S., Cesarman, G. M., Jacovina, A. T., et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med, 1999; 340: 994-1004.
154. Di, Bona E., Avvisati, G., Castaman, G., et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol, 2000; 108: 689-95.
155. Creutzig, U., Ritter, J., Budde, M., et al. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenousleukemia. Associations with hyperleukocytosisandacute monocytic leukemia. Cancer, 1987; 60: 3071-9.
156. Liso, V., Specchia, G., Pogliani, E. M., et al. Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases. Cancer, 1998; 83: 1522-8.
157. Evans, G., Grimwade, D., Prentice, H. G., et al. Central nervous system relapse in acute promyelocytic leukaemia in patients treated with all-trans retinoic acid. Br J Haematol, 1997; 98: 437-9.
158. Ko, B. S., Tang, J. L., Chen, Y. C., et al. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia-the occurrence of retinoic acid syndrome is a risk factor. Leukemia, 1999; 13: 1406-8.
159. Specchia, G., Lo, C. F., Vignetti, M., et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol, 2001; 19: 4023-8.
160. Katsura, Y. Redefinition of lymphoid progenitors. Nat Rev Immunol, 2002; 2: 127-32.
161. Lee, E. J., Pollak, A., Leavitt, R.D., et al. Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Blood, 1987; 70: 1400-6.
162. Bennett, J. M., Catovsky, D., Daniel, M. T., et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol, 1991; 78: 325-9.
163. Kuzmanovic, M., Rasovic, N., Bunjevacki, G., et al. Minimally differentiated acute myeloid leukemia (AML-M0) in children: a single center experience. Med Pediatr Oncol, 2000; 34: 364-5.
164. Huang, S. Y., Tang, J. L., Jou, S. T., et al. Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years. Leukemia, 1999; 13: 1506-12.
165. Kotylo, P. K., Seo, I. S., Smith, F. O., et al. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0). Am J Clin Pathol, 2000; 113: 193-200.
166. Roumier, C., Eclache, V., Imbert, M., et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood, 2003; 101: 1277-83.
167. Matutes, E., Morilla, R., Farahat, N., et al. Definition of acute biphenotypic leukemia. Haematologica, 1997; 82: 64-6.
168. Kantarjian, H. M., Hirsch-Ginsberg, C., Yee, G., et al. Mixedlineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood, 1990; 76: 808-13.
169. Cross, A. H., Goorha, R. M., Nuss, R., et al. Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity. Blood, 1988; 72: 579-87.
170. Creutzig, U., Harbott, J., Sperling, C., et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood, 1995;86: 3097-108.
171. Killick, S., Matutes, E., Powles, R. L., et al. Outcome of biphenotypic acute leukemia. Haematologica, 1999; 84: 699-706.
172. Mirro, J., Zipf, T. F., Pui, C. H., et al. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. Blood, 1985; 66: 1115-23.
173. Legrand, O., Perrot, J. Y., Simonin, G., et al. Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein overexpression. Br J Haematol, 1998; 100: 147-55.
174. Hurwitz, C. A., Mounce, K. G., & Grier, H. E. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. J Pediatr Hematol Oncol, 1995; 17: 185-97.
175. Creutzig, U., Ritter, J., Zimmermann, M., et al. Idarubicin improves blast cell clearance during induction therapy in children with AML:results of study AML-BFM93.AML-BFMStudy Group. Leukemia, 2001; 15: 348-54.
176. Hann, I. M., Stevens, R. F., Goldstone, A. H., et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AMLtrial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood, 1997; 89: 2311-18.
177. Arnaout, M. K., Radomski, K. M., Srivastava, D. K., et al. Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short-and long-term effects. Leukemia, 2000; 14: 1736-42.
178. Crews, K. R., Gandhi, V., Srivastava, D. K., et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol, 2002; 20: 4217-24.
179. Carella, A. M., Berman, E., Maraone, M. P., et al. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. Haematologica, 1990; 75: 159-69.
180. Berman, E.&McBride, M. Comparative cellular pharmacology of daunorubicin and idarubicin inhumanmultidrug-resistant leukemia cells. Blood, 1992; 79: 3267-73.
181. Hollingshead, L. M. & Faulds, D. Idarubicin. A review of its pharmacodynamicandpharmacokineticproperties, andtherapeutic potential in the chemotherapy of cancer. Drugs, 1991; 42: 690-719.
182. Becton, D., Ravindranath, Y. & Dahl, G. V. A phase III study of intensive cytarabine (Ara-C) induction followed by cyclosporine (CSA) modulation of drug resistance in de novo pediatric AML: POG 9421. Blood, 2001; 98: 461, abstract 1929.
183. Rees, J. K., Gray, R. G., & Wheatley, K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9study. MRC Leukaemia in Adults Working Party. Br J Haematol, 1996; 94: 89-98.
184. Lowenberg, B., Putten, W. van, Theobald, M., et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acutemyeloid leukemia. NEngl J Med, 2003; 349: 743-52.
185. Cassileth, P. A., Begg, C. B., Silber, R., et al. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. Cancer Treat Rep, 1987; 71: 137-40.
186. Cassileth, P. A., Andersen, J.W., Bennett, J. M., et al. Escalating the intensity of post-remission therapy improves the outcome in acutemyeloid leukemia: the ECOGexperience. The Eastern Cooperative Oncology Group. Leukemia, 1992; 6 (Suppl. 2): 116-19.
187. Dahl, G. V., Kalwinsky, D. K., Murphy, S., et al. Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia. Blood, 1982; 60: 856-63.
188. Baehner, R. L., Kennedy, A., Sather, H., et al. Characteristics of children with acute nonlymphocytic leukemia in long-term continuous remission: a report for Childrens Cancer Study Group. Med Pediatr Oncol, 1981; 9: 393-403.
189. Weinstein, H. J., Mayer, R. J., Rosenthal, D. S., et al. Treatment of acute myelogenous leukemia in children and adults. NEngl J Med, 1980; 303: 473-8.
190. Wells, R. J., Woods, W. G., Lampkin, B. C., et al. Impact of highdose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. J Clin Oncol, 1993; 11: 538-45.
191. Ritter, J., Creutzig, U., & Schellong, G. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and-87. AML-BFM-Group. Leukemia, 1992; 6 (Suppl. 2): 59-62.
192. Kamps, W. A., Veerman, A. J., Wering, E. R. Van, et al. Longterm follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia, 2000; 14: 2240-6.
193. Wells, R. J., Woods, W. G., Buckley, J. D., et al. Treatment of newly diagnosed children and adolescents with acutemyeloid leukemia: a Childrens Cancer Group study. J Clin Oncol, 1994; 12: 2367-77.
194. Mayer, R. J., Davis, R. B., Schiffer, C. A., et al. Intensive postremission chemotherapy in adults with acutemyeloid leukemia. Cancer and Leukemia Group B. N Engl J Med, 1994; 331: 896-903.
195. Buchner, T., Hiddemann, W., Wormann, B., et al. Doubleinduction strategy for acute myeloid leukemia: the effect of highdose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the GermanAMLCooperative Group. Blood, 1999; 93: 4116-24.
196. Feig, S. A., Lampkin, B., Nesbit, M. E., et al. Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the Children's Cancer Group. Bone Marrow Transplant, 1993; 12: 65-71.
197. Bloomfield, C. D., Lawrence, D., Byrd, J. C., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res, 1998; 58: 4173-9.
198. Byrd, J. C., Dodge, R. K., Carroll, A., et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of highdose cytarabine are administered. J Clin Oncol, 1999; 17: 3767-75.
199. Santos, G. W., Tutschka, P. J., Brookmeyer, R., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfanandcyclophosphamide. N Engl J Med, 1983; 309: 1347-53.
200. Forman, S. J., Spruce, W. E., Farbstein, M. J., et al. Bone marrow ablation followed by allogeneic marrow grafting during first completeremissionofacutenonlymphocyticleukemia. Blood, 1983; 61: 439-42.
201. Dahl, G. V., Kalwinsky, D. K., Mirro, J., Jr., et al. Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. J Clin Oncol, 1990; 8: 295-303.
202. Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid Cambridge Books Online (c) Cambridge University Press, 2009 Acute myeloid leukemia 533 leukemia in first remission. N Engl J Med, 1998; 339: 1649-56.
203. Amadori, S., Testi, A. M., Arico, M., et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol, 1993; 11: 1046-54.
204. Michel, G., Leverger, G., Leblanc, T., et al. Allogeneic bonemarrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant, 1996; 17: 191-6.
205. Burnett, A. K., Goldstone, A. H., Stevens, R. M., et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet, 1998; 351: 700-8.
206. Burnett, A. K., Wheatley, K., Goldstone, A. H., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol, 2002; 118: 385-400.
207. Nesbit, M. E., Jr., Buckley, J. D., Feig, S. A., et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. J Clin Oncol, 1994; 12: 127-35.
208. Creutzig, U. & Reinhardt, D. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-a European view. Br J Haematol, 2002; 118: 365-77.
209. Chen, A. R., Alonzo, T. A., Woods, W. G., et al. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrowtransplantation?-an American view. Br J Haematol, 2002; 118: 378-84.
210. Creutzig, U., Ritter, J., & Schellong, G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood, 1990; 75: 1932-40.
211. Walter, A.W., Hancock, M. L., Pui, C. H., et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol, 1998; 16: 3761-7.
212. Loning, L., Zimmermann, M., Reiter, A., et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood, 2000; 95: 2770-5.
213. Hasle, H., Helgestad, J., Christensen, J. K., et al. Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: long-termfollowupwith cerebral computed tomography scans and endocrinological studies. Eur J Pediatr, 1995; 154: 24-9.
214. Leung, W., Hudson, M.M., Strickland, D. K., et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol, 2000; 18: 3273-9.
215. Woods, W. G., Kobrinsky, N., Buckley, J., et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. J Clin Oncol, 1993; 11: 1448-57.
216. Abbott, B. L., Rubnitz, J. E., Tong, X., et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acutemyeloid leukemia: a single institution's experience. Leukemia, 2003; 17: 2090-6.
217. Mahmoud, H.H., Rivera, G. K., Hancock, M.L., et al. Lowleukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. NEngl J Med, 1993; 329: 314-19.
218. Pui, C. H. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol, 2003; 21: 179-81.
219. Razzouk, B. I., Raimondi, S. C., Srivastava, D. K., et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia, 2001; 15: 1326-30.
220. Rubnitz, J. E., Raimondi, S. C., Tong, X., et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol, 2002; 20: 2302-9.
221. Hsu, C. A., Rishi, A. K., Su-Li, X., et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptorindependent pathway. Blood, 1997; 89: 4470-9.
222. Calleja, E. M. &Warrell, R. P., Jr. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia. Curr Oncol Rep, 2000; 2: 519-23.
223. Tallman, M. S., Andersen, J. W., Schiffer, C. A., et al. All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med, 1997; 337: 1021-8.
224. De Botton, S., Coiteux, V., Chevret, S., et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol, 2004; 22: 1404-12.
225. Paietta, E., Andersen, J., Racevskis, J., et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acutemyeloid leukemia: immunological, molecular and functional analyses. Leukemia, 1994; 8: 968-73.
226. Michieli, M., Damiani, D., Ermacora, A., et al. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Br J Haematol, 2000; 108: 703-9.
227. Bernard, J., Weil, M., Boiron, M., et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood, 1973; 41: 489-96.
228. Avvisati, G., Mandelli, F., Petti, M. C., et al. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol, 1990; 44: 257-60.
229. Head, D., Kopecky, K. J., Weick, J., et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood, 1995; 86: 1717-28.
230. Chen, Z. X., Xue, Y. Q., Zhang, R., et al. Aclinicalandexperimentalstudyonall-transretinoic acid-treatedacutepromyelocytic leukemia patients. Blood, 1991; 78: 1413-19.
231. Fenaux, P., Le Deley, M. C., Castaigne, S., et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia.Results of a multicenter randomized trial. European APL 91 Group. Blood, 1993; 82: 3241-9.
232. De Botton, S., Dombret, H., Sanz, M., et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood, 1998; 92: 2712-18.
233. Fenaux, P., Chastang, C., Chevret, S., et al. A randomized comparisonof all transretinoicacid(ATRA) followed by chemotherapy and ATRAplus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood, 1999; 94: 1192-200.
234. Vahdat, L., Maslak, P., Miller, W. H., Jr., et al. Earlymortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RARalpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood, 1994; 84: 3843-9.
235. Avvisati, G., Lo, Coco F., Diverio, D., et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood, 1996; 88: 1390-8.
236. Sanz, M. A., Martin, G., Rayon, C., et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa positive acute promyelocytic leukemia. Blood, 1999; 94: 3015-21.
237. Estey, E., Thall, P. F., Pierce, S., et al. Treatment of newly diagnosedacutepromyelocyticleukemiawithoutcytarabine. J Clin Oncol, 1997; 15: 483-90.
238. Mandelli, F., Diverio, D., Avvisati, G., et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood, 1997; 90: 1014-21.
239. Rowe, J. M. Uncertainties in the standard care of acute myelogenous leukemia. Leukemia, 2001; 15: 677-9.
240. Testi, A. M., Biondi, A., Lo, C. F., et al. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood, 2005; 106: 447-53.
241. Shen, Z. X., Chen, G. Q., Ni, J. H., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997; 89: 3354-60.
242. Niu, C., Yan, H., Yu, T., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999; 94: 3315-24.
243. Chen, G. Q., Shi, X. G., Tang, W., et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exertsdose-dependentdualeffectson APLcells. Blood, 1997; 89: 3345-53.
244. Jing, Y., Dai, J., Chalmers-Redman, R. M., et al. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 1999; 94: 2102-11.
245. Soignet, S. L., Maslak, P., Wang, Z. G., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. NEngl J Med, 1998; 339: 1341-8.
246. Soignet, S. L., Frankel, S. R., Douer, D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 2001; 19: 3852-60.
247. Camacho, L. H., Soignet, S. L., Chanel, S., et al. Leukocytosis and the retinoic acid syndromein patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol, 2000; 18: 2620-5.
248. Unnikrishnan, D., Dutcher, J. P., Varshneya, N., et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood, 2001; 97: 1514-16.
249. Westervelt, P., Brown, R. A., Adkins, D. R., et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood, 2001; 98: 266-71.
250. Jing, Y., Wang, L., Xia, L., et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood, 2001; 97: 264-9.
251. Estey, E. H., Giles, F. J., Beran, M., et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood, 2002; 99: 4222-4.
252. Ravindranath, Y., Abella, E., Krischer, J. P., et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood, 1992; 80: 2210-4.
253. Taub, J.W., Huang, X., Matherly, L. H., et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood, 1999; 94: 1393-400.
254. Ge, Y., Jensen, T., James, S. J., et al. High frequency of the 844ins68 cystathionine-beta-synthase gene variant in Down syndrome children with acute myeloid leukemia. Leukemia, 2002; 16: 2339-41.
255. Galmarini, C. M., Thomas, X., Calvo, F., et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol, 2002; 117: 860-8.
256. Gati, W.P., Paterson, A. R., Belch, A. R., et al. Esnucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk Lymphoma, 1998; 32: 45-54.
257. Galmarini, C. M., Thomas, X., Graham, K., et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells Cambridge Books Online (c) Cambridge University Press, 2009 Acute myeloid leukemia 535 predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol, 2003; 122: 53-60.
258. Davies, S. M., Robison, L. L., Buckley, J. D., et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol, 2001; 19: 1279-87.
259. Naoe, T., Tagawa, Y., Kiyoi, H., et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia, 2002; 16: 203-8.
260. Voso, M. T., D'Alo, F., Putzulu, R., et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acutemyeloid leukemia. Blood, 2002; 100: 2703-7.
261. Illmer, T., Schuler, U. S., Thiede, C., et al. MDR1 gene polymorphisms affect therapy outcome in acutemyeloid leukemia patients. Cancer Res, 2002; 62: 4955-62.
262. Delaunay, J., Vey, N., Leblanc, T., et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood, 2003; 102: 462-9.
263. Rubnitz, J. E., Raimondi, S. C., Halbert, A. R., et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience. Leukemia, 2002; 16: 2072-7.
264. Nguyen, S., Leblanc, T., Fenaux, P., et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood, 2002; 99: 3517-23.
265. Raimondi, S. C., Kalwinsky, D. K., Hayashi, Y., et al. Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet Cytogenet, 1989; 40: 13-27.
266. Dimartino, J.F.&Cleary, M.L. Mll rearrangementsinhaematological malignancies: lessons fromclinicalandbiological studies. Br J Haematol, 1999; 106: 614-26.
267. Mrozek, K., Heinonen, K., Lawrence, D., et al. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood, 1997; 90: 4532-8.
268. Sandoval, C., Head, D. R., Mirro, J., Jr., et al. Translocation t(9;11)(p21;q23) in pediatric de novo and secondary acute myeloblastic leukemia. Leukemia, 1992; 6: 513-19.
269. Martinez-Climent, J. A., Lane, N. J., Rubin, C. M., et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia, 1995; 9: 95-101.
270. Odom, L. F., Gordon, E. M. Acute monoblastic leukemia in infancy and early childhood: successful treatment with an epipodophyllotoxin. Blood, 1984; 64: 875-82.
271. Nishikawa, A., Nakamura, Y., Nobori, U., et al. Acute monocytic leukemia in children. Response to VP-16-213 as a single agent. Cancer, 1987; 60: 2146-9.
272. Zwaan, C. M., Kaspers, G. J., Pieters, R., et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood, 2002; 100: 3352-60.
273. Shiah, H. S., Kuo, Y. Y., Tang, J. L., et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia, 2002; 16: 196-202.
274. Pagano, L., Pulsoni, A., Vignetti, M., et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia, 2002; 16: 1622-6.
275. Pui, C. H. & Relling, M. V. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol, 2000; 109: 13-23.
276. Hale, G. A., Heslop, H. E., Bowman, L. C., et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant, 1999; 24: 735-9.
277. Luna-Fineman, S., Shannon, K. M., Atwater, S. K., et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood, 1999; 93: 459-66.
278. Sasaki, H., Manabe, A., Kojima, S., et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia, 2001; 15: 1713-20.
279. Mrozek, K., Heinonen, K., & Bloomfield, C. D. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol, 2001; 14: 19-47.
280. Asou, N., Adachi, K., Tamura, J., et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol, 1998; 16: 78-85.
281. Chou, W. C., Tang, J. L., Yao, M., et al. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Leukemia, 1997; 11: 921-8.
282. Albitar, M., Chang, K. S., Pierce, S., et al. The short form of PMLRARalpha fusion transcript is associated with poor survival. Leuk Res, 1999; 23: 89-92.
283. Fukutani, H., Naoe, T., Ohno, R., et al. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia, 1995; 9: 1478-82.
284. Gallagher, R. E., Willman, C. L., Slack, J. L., et al. Association of PML-RAR_ fusionm RNAtype with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood, 1997; 90: 1656-63.
285. Ferrara, F., Morabito, F., Martino, B., et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-transretinoic acid and chemotherapy. J Clin Oncol, 2000; 18: 1295-300.
286. Bolognesi, E., Cimino, G., Diverio, D., et al. HLA class I in acute promyelocytic leukemia (APL): possible correlation with clinical outcome. Leukemia, 2000; 14: 393-8.
287. Jurcic, J. G., Caron, P. C., Miller, W. H., Jr., et al. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia, 1995; 9: 244-8.
288. Kiyoi, H., Naoe, T., Nakano, Y., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood, 1999; 93: 3074-80.
289. Lacayo, N. J., Meshinchi, S., Kinnunen, P., et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood, 2004; 104: 2646-54.
290. Abu-Duhier, F. M., Goodeve, A. C., Wilson, G. A., et al. FLT3 internal tandem duplication mutations in adult acutemyeloid leukaemia define a high-risk group. Br J Haematol, 2000; 111: 190-5.
291. Kottaridis, P. D., Gale, R. E., Frew, M. E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 2001; 98: 1752-9.
292. Meshinchi, S., Woods, W. G., Stirewalt, D. L., et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, 2001; 97: 89-94.
293. Frohling, S., Schlenk, R. F., Breitruck, J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years)with acute myeloidleukemiaandnormal cytogenetics:a study of the AMLStudy Group Ulm. Blood, 2002; 100: 4372-80.
294. Zwaan, C. M., Meshinchi, S., Radich, J. P., et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 2003; 102: 2387-94.
295. Whitman, S. P., Archer, K. J., Feng, L., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res, 2001; 61: 7233-9.
296. Boissel, N., Cayuela, J. M., Preudhomme, C., et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia, 2002; 16: 1699-704.
297. Schnittger, S., Schoch, C., Dugas, M., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 2002; 100: 59-66.
298. Inokuchi, K., Yamaguchi, H., Hanawa, H., et al. Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clin Cancer Res, 2002; 8: 1882-8.
299. De Bont, E. S., Fidler, V., Meeuwsen, T., et al. Vascular endothelial growthfactor secretion isanindependentprognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res, 2002; 8: 2856-61.
300. Kohler, T., Schill, C., Deininger, M.W., et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia, 2002; 16: 22-9.
301. Del Poeta, G., Venditti, A., Del Principe, M. I., et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood, 2003; 101: 2125-31.
302. Valk, P. J., Verhaak, R. G., Beijen, M. A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med., 2004; 350: 1617-28.
303. Bullinger, L., Dohner, K., Bair, E., et al. Use of geneexpression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med, 2004; 350: 1605-16.
304. Leith, C. P., Kopecky, K. J., Chen, I. M., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 1999; 94: 1086-99.
305. Legrand, O., Simonin, G., Beauchamp-Nicoud, A., et al. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood, 1999; 94: 1046-56.
306. Boer, M. L. den, Pieters, R., Kazemier, K. M., et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood, 1998; 91: 2092-8.
307. Steinbach, D., Sell, W., Voigt, A., et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acutemyeloid leukemia. Leukemia, 2002; 16: 1443-7.
308. Heuvel-Eibrink, M. M. van den, Wiemer, E. A., Prins, A., et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia, 2002; 16: 833-9.
309. Kolk, D.M. vander, Vellenga, E., Scheffer, G. L., et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood, 2002; 99: 3763-70.
310. Abbott, B. L., Colapietro, A. M., Barnes, Y., et al. Low levels of ABCG2 expression in adult AML blast samples. Blood, 2002; 100: 4594-601.
311. Gaynon, P. S., Desai, A. A., Bostrom, B. C., et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer, 1997; 80: 1717-26.
312. Campana, D. & Coustan-Smith, E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol, 2002; 15: 1-19.
313. Pui, C. H. & Campana, D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia, 2000; 14: 783-5.
314. Szczepanski, T., Orfao, A., Velden, V. H. van der, et al. Minimal residual disease in leukaemia patients. Lancet Oncol, 2001; 2: 409-17.
315. Creutzig, U., Zimmermann, M., Ritter, J., et al. Definition of a standard-risk group in children with AML. Br J Haematol, 1999; 104: 630-9.
316. Kern, W., Haferlach, T., Schoch, C., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-termoutcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial. Blood, 2003; 101: 64-70.
317. San Miguel, J. F., Vidriales, M. B., & Orfao, A. Immunological evaluation ofminimalresidual disease(MRD)inacutemyeloid leukaemia (AML). Best Pract Res Clin Haematol, 2002; 15: 105-18.
318. Coustan-Smith, E., Ribeiro, R. C., Rubnitz, J. E., et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol, 2003; 123: 243-52.
319. Sievers, E. L., Lange, B. J., Buckley, J. D., et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flowcytometry. J Natl Cancer Inst, 1996; 88: 1483-8.
320. Sievers, E. L., Lange, B. J., Alonzo, T. A., et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood, 2003; 101: 3398-406.
321. San Miguel, J. F., Martinez, A., Macedo, A., et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, 1997; 90: 2465-70.
322. Venditti, A., Buccisano, F., Del Poeta, G., et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood, 2000; 96: 3948-52.
323. San Miguel, J. F., Vidriales, M. B., Lopez-Berges, C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood, 2001; 98: 1746-51.
324. Yin, J. A. & Grimwade, D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet, 2002; 360: 160-2.
325. Schnittger, S., Weisser, M., Schoch, C., et al. Newscore predicting for prognosis in PML-+, AML1-ETO+, or CBFBMYH11+ acutemyeloidleukemiabasedonquantificationoffusiontranscripts. Blood, 2003; 102: 2746-55.
326. Lo, C. F., Diverio, D., Avvisati, G., et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood, 1999; 94: 2225-9.
327. Tobal, K., Newton, J., Macheta, M., et al. Molecularquantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood, 2000; 95: 815-19.
328. Buonamici, S., Ottaviani, E., Testoni, N., et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood, 2002; 99: 443-9.
329. Guerrasio, A., Pilatrino, C., De Micheli, D., et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RTPCR amplification of fusion transcripts. Leukemia, 2002; 16: 1176-81.
330. Viehmann, S., Teigler-Schlegel, A., Bruch, J., et al. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETOrearrangement. Leukemia, 2003; 17: 1130-6.
331. Trka, J., Kalinova, M., Hrusak, O., et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia, 2002; 16: 1381-9.
332. Cilloni, D., Gottardi, E., De Micheli, D., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia, 2002; 16: 2115-21.
333. Lo, C. F., Avvisati, G., Diverio, D., et al. Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. Blood, 1991; 77: 1657-9.
334. Miller, W. H., Jr., Kakizuka, A., Frankel, S. R., et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 1992; 89: 2694-8.
335. Diverio, D., Rossi, V., Avvisati, G., et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMAAIEOP multicenter "AIDA" trial. GIMEMA-AIEOPMulticenter "AIDA" Trial. Blood, 1998; 92: 784-9.
336. Ikeda, K., Sasaki, K., Tasaka, T., et al. Reverse transcriptionpolymerase chain reaction for PML-RAR alpha fusion transcripts in acute promyelocytic leukemia and its application to minimal residual leukemia detection. Leukemia, 1993; 7: 544-8.
337. Fukutani, H., Naoe, T., Ohno, R., et al. Prognostic significance of the RT-PCRassay of PML-RARa transcripts in acute promyelocytic leukemia. The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). Leukemia, 1995; 9: 588-93.
338. Burnett, A. K., Grimwade, D., Solomon, E., et al. Presenting whitebloodcellcountandkinetics ofmolecularremissionpredict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood, 1999; 93: 4131-43.
339. Lo, C. F., Diverio, D., Falini, B., et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood, 1999; 94: 12-22.
340. Cassinat, B., Zassadowski, F., Balitrand, N., et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia, 2000; 14: 324-8.
341. Tobal, K., Moore, H., Macheta, M., et al. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive competitive RTPCR method. Leukemia, 2001; 15: 1060-5.
342. Rubnitz, J. E., Lensing, S., Zhou, Y., et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer, 2004; 101: 1677-84.
343. Okamoto, Y., Ribeiro, R. C., Srivastava, D. K., et al. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol, 2003; 25: 696-703.
344. Pizzo, P. A. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med, 1993; 328: 1323-32.
345. Freifeld, A., Marchigiani, D., Walsh, T., et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. NEngl J Med, 1999; 341: 305-11.
346. Gamis, A. S., Howells, W. B., De Swarte-Wallace, J., et al. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's Cancer Group Study CCG-2891. J Clin Oncol, 2000; 18: 1845-55.
347. Walsh, T. J., Pappas, P., Winston, D. J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. NEngl J Med, 2002; 346: 225-34.
348. Herbrecht, R., Denning, D.W., Patterson, T. F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. NEngl J Med, 2002; 347: 408-15.
349. Estey, E. H. Growth factors in acute myeloid leukaemia. Best Pract Res Clin Haematol, 2001; 14: 175-87.
350. Godwin, J. E., Kopecky, K. J., Head, D. R., et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood, 1998; 91: 3607-15.
351. Amadori, S., Suciu, S., Jehn, U., et al. Use of glycosylated recombinanthumanG-CSF(lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase 3 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC/GIMEMA) Leukemia Groups. Blood, 2005; 106: 27-34.
352. Rowe, J. M., Andersen, J. W., Mazza, J. J., et al. A randomized placebo-controlled phase III study of granulocytemacrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood, 1995; 86: 457-62.
353. Alonzo, T. A., Kobrinsky, N. L., Aledo, A., et al. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. J Pediatr Hematol Oncol, 2002; 24: 627-35.
354. Frankel, S. R., Eardley, A., Heller, G., et al. All-trans retinoic acid for acute promyelocytic leukemia.Results of the New York Study. Ann Intern Med, 1994; 120: 278-86.
355. Tallman, M. S., Andersen, J. W., Schiffer, C. A., et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood, 2000; 95: 90-5.
356. Wiley, J. S. & Firkin, F. C. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia, 1995; 9: 774-8.
357. Bargetzi, M. J., Tichelli, A., Gratwohl, A., et al. [Oral Alltransretinoic acid administration in intubated patients with acute promyelocytic leukemia]. Schweiz Med Wochenschr, 1996; 126: 1944-5.
358. Estey, E. H., Giles, F. J., Kantarjian, H., et al. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood, 1999; 94: 2230-5.
359. Douer, D., Estey, E., Santillana, S., et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood, 2001; 97: 73-80.
360. Smith, M. A., Adamson, P. C., Balis, F. M., et al. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol, 1992; 10: 1666-73.
361. Mahmoud, H. H., Hurwitz, C. A., Roberts, W. M., et al. Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet, 1993; 342: 1394-5.
362. Krischer, J. P., Epstein, S., Cuthbertson, D. D., et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group Experience. J Clin Oncol, 1997; 15: 1544-52.
363. Pui, C. H. & Relling, M. V. Topoisomerase II inhibitorrelated acute myeloid leukaemia. Br J Haematol, 2000; 109: 13-23.
364. Micallef, I. N., Lillington, D. M., Apostolidis, J., et al. Therapyrelated myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol, 2000; 18: 947-55.
365. Sandoval, C., Pui, C. H., Bowman, L. C., et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol, 1993; 11: 1039-45.
366. Aquino, V. M., Schneider, N. R., & Sandler, E. S. Secondary myelodysplasia with monosomy 7 arising after treatment for acute lymphoblastic leukemia in childhood. J Pediatr Hematol Oncol, 2001; 23: 48-50.
367. Pui, C.H., Relling, M.V., Rivera, G.K., et al. Epipodophyllotoxinrelated acutemyeloid leukemia: a study of 35 cases. Leukemia, 1995; 9: 1990-6.
368. Pulsoni, A., Pagano, L., Lo, C. F., et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as Cambridge Books Online (c) Cambridge University Press, 2009 Acute myeloid leukemia 539 a second tumor: the GIMEMA experience. Blood, 2002; 100: 1972-6.
369. Beaumont, M., Sanz, M., Carli, P. M., et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol, 2003; 21: 2123-37.
370. Latagliata, R., Petti, M. C., Fenu, S., et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood, 2002; 99: 822-4.
371. Giles, F. J., Garcia-Manero, G., Cortes, J. E., et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol, 2002; 20: 656-64.
372. Rizzieri, D. A., Bass, A. J., Rosner, G. L., et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol, 2002; 20: 674-9.
373. Gandhi, V., Plunkett, W., Du, M., et al. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol, 2002; 20: 665-73.
374. Seiter, K., Liu, D., Loughran, T., et al. Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol, 2002; 20: 3249-53.
375. Sievers, E. L., Appelbaum, F. R., Spielberger, R.T., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 1999; 93: 3678-84.
376. Sievers, E. L., Larson, R. A., Stadtmauer, E. A., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol, 2001; 19: 3244-54.
377. Larson, R. A., Boogaerts, M., Estey, E., et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 2002; 16: 1627-36.
378. Zwaan, C. M., Reinhardt, D., Corbacioglu, S., et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood, 2003; 101: 3868-71.
379. Wadleigh, M., Richardson, P. G., Zahrieh, D., et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 2003; 102: 1578-82.
380. Daskalakis, M., Nguyen, T. T., Nguyen, C., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood, 2002; 100: 2957-64.
381. Silverman, L. R., Demakos, E. P., Peterson, B. L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the cancerandleukemia group B. J Clin Oncol, 2002; 20: 2429-40.
382. Byrd, J. C., Marcucci, G., Parthun, M. R., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 2005; 105: 959-67.
383. Gore, S. D., Weng, L. J., Figg, W. D., et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res, 2002; 8: 963-70.
384. Sandor, V., Bakke, S., Robey, R. W., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res, 2002; 8: 718-28.
385. Brown, P., Meshinchi, S., Levis, M., et al. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood, 2004; 104: 1841-9.
386. Kelly, L. M., Yu, J. C., Boulton, C. L., et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 2002; 1: 421-32.
387. Weisberg, E., Boulton, C., Kelly, L. M., et al. Inhibition ofmutant FLT3receptors in leukemia cellsby the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell, 2002; 1: 433-43.
388. Zheng, R., Friedman, A. D., & Small, D. Targeted inhibition of FLT3 overcomes the block tomyeloid differentiation in 32Dcl3 cellscausedbyexpression of FLT3/ITDmutations. Blood, 2002; 100: 4154-61.
389. Stone, R. M., De Angelo, D. J., Klimek, V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005; 105: 54-60.
390. Lie, S. O., Abrahamsson, J., Clausen, N., et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol, 2003; 122: 217-25.